Friday, August 29, 2025

The company will now apply for FDA approval, so the drug can be self-administered by patients at home.

Wednesday, August 27, 2025

BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophrenia No discontinuations for

Wednesday, August 27, 2025

BXCL501 achieved SERENITY At-Home’s primary endpoint of being well tolerated in the at-home treatment of agitation episodes in patients with bipolar disorders or schizophreniaNo discontinuations for t

Tuesday, August 26, 2025

Company to host conference call at 8 a.m. ET, August 27, 2025NEW HAVEN, Conn., Aug. 26, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artifi

Tuesday, August 19, 2025

Data from more than 2,600 agitation episodes collected Topline data readout is on track for August NEW HAVEN, Conn., Aug. 19, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biop

Monday, August 18, 2025

Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home (Outpatient) setting sNDA submission on track for Q1 2026 NEW HAVEN, Conn., Aug. 18, 2025 (GLOBE NEWSWIRE) --

Wednesday, August 13, 2025

NasdaqCM:BTAI 1 Year Share Price vs Fair Value Explore BioXcel Therapeutics's Fair Values from the Community and select...

Wednesday, August 13, 2025

Several stocks have shown strong momentum in recent sessions as broader markets charge to all-time highs. Here’s a look at some standout momentum movers that are just starting to pick up steam. 3 Mome

Wednesday, August 13, 2025

NEW HAVEN, Conn., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur

Tuesday, August 12, 2025

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of -6.52% and -52.00%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Tuesday, August 12, 2025

Topline data from SERENITY At-Home Phase 3 trial for acute treatment of agitation associated with bipolar disorders or schizophrenia expected in August FDA meeting scheduled in August and is intended

Monday, August 11, 2025

NEW HAVEN, Conn., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur

Wednesday, August 6, 2025

Dexmedetomidine demonstrated a significant reduction in stress-induced behaviors, suggesting potential applications of BXCL501 in chronic psychiatric disorders in addition to treatment of acute agitat

Monday, August 4, 2025

Gibo Holdings Ltd. 34,392,022 0.061

Friday, August 1, 2025

Vast majority of patients dosed completed the full 12-week study Data from more than 2,200 agitation episodes collected Topline data readout anticipated this month NEW HAVEN, Conn., Aug. 01, 2025 (GLO

Monday, July 21, 2025

Company focused on obtaining approval for outpatient (at-home) use of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia Pre-Supplemental New Drug Applicat

Monday, July 14, 2025

Capricor slumps 33% as the FDA rejects its BLA for DMD drug, deramiocel, citing lack of effectiveness data and CMC issues.

Friday, July 11, 2025

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) is among the fundamentally strong penny stocks to invest in. H.C. Wainwright analysts have reiterated their Buy rating on BioXcel Therapeutics, Inc. (NASDAQ:BT

Tuesday, July 1, 2025

DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., July 01, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutica

Tuesday, May 27, 2025

DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical

Tuesday, May 27, 2025

NEW HAVEN, Conn., May 27, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuro

Monday, May 12, 2025

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 44.85% and 44%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Monday, May 12, 2025

Enrollment complete in SERENITY At-Home pivotal Phase 3 safety trial for acute treatment of agitation associated with bipolar disorders or schizophrenia Topline data expected in second half of 2025 in

Saturday, March 29, 2025

BioXcel Therapeutics ( NASDAQ:BTAI ) Full Year 2024 Results Key Financial Results Net loss: US$59.6m (loss narrowed by...

Thursday, March 27, 2025

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 18.12% and 144%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Thursday, March 27, 2025

Enrollment exceeds 60% of required number of patients in SERENITY At-Home pivotal Phase 3 safety trial evaluating 200 patients for acute treatment of agitation associated with bipolar disorders or sch

Wednesday, March 19, 2025

Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.

Tuesday, March 11, 2025

Topline data expected in second half of 2025 to support potential sNDA submission for label expansion of IGALMI® in the home setting Company has $35M of cash following closing of recent equity financi

Sunday, March 9, 2025

We recently compiled a list of the 10 Micro-, Small-Cap Firms Were Last Week’s Top Performers. In this article, we are going to take a look at where BioXcel Therapeutics, Inc. (NASDAQ:BTAI) stands aga

Friday, March 7, 2025

Data to support potential sNDA submission for label expansion of IGALMI® in the home setting Topline data expected in second half of 2025 NEW HAVEN, Conn., March 07, 2025 (GLOBE NEWSWIRE) -- BioXcel T

Wednesday, March 5, 2025

ScPharmaceuticals (SCPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tuesday, March 4, 2025

NEW HAVEN, Conn., March 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative

Tuesday, March 4, 2025

BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Monday, March 3, 2025

NEW HAVEN, Conn., March 03, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative

Monday, March 3, 2025

FDA concludes site inspection is closed under 21 C.F.R.20.64(d)(3); Voluntary Action Indicated Company believes this further supports reliability of data from TRANQUILITY II trial of BXCL501 NEW HAVEN

Friday, February 28, 2025

NEW HAVEN, Conn., Feb. 28, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur

Thursday, February 6, 2025

NEW HAVEN, Conn., Feb. 06, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur

Wednesday, February 5, 2025

Patient enrollment advancing in SERENITY At-Home Phase 3 trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia Developed plans for TRANQUILITY In-Care Ph

Monday, December 23, 2024

BioXcel Therapeutics (BTAI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Friday, November 22, 2024

NEW HAVEN, Conn., Nov. 22, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop trans

Thursday, November 21, 2024

NEW HAVEN, Conn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop trans

Friday, November 15, 2024

BioXcel Therapeutics Inc (BTAI) reports significant progress in pivotal trials and improved financial metrics despite revenue challenges.

Friday, November 15, 2024

Q3 2024 BioXcel Therapeutics Inc Earnings Call

Thursday, November 14, 2024

BioXcel Therapeutics (BTAI) delivered earnings and revenue surprises of 36% and 82.17%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Thursday, November 14, 2024

Advancing two pivotal Phase 3 trials of BXCL501 for acute treatment of agitation associated with bipolar disorders, schizophrenia, and Alzheimer’s dementia Conference call set for 8:00 a.m. ET today N

Thursday, November 14, 2024

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Conference Call November 14, 2024 8:00 AM ETCompany ParticipantsVimal Mehta - Chief Executive...

Tuesday, November 12, 2024

First patient randomized in SERENITY At-Home trial of BXCL501 for acute treatment of agitation associated with bipolar disorders or schizophrenia Received FDA feedback on protocol for TRANQUILITY In-C

Friday, November 8, 2024

NEW HAVEN, Conn., Nov. 08, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur

Tuesday, November 5, 2024

BioXcel Therapeutics (BTAI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tuesday, October 29, 2024

NEW HAVEN, Conn., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neur

Monday, October 21, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Monday, October 21, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, October 15, 2024

Phase 2a efficacy and safety trial enrollment initiation expected in H1 2025 ~40 million Americans go to emergency department annually after a traumatic experience 1 Second externally funded stress-re

Tuesday, October 15, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Tuesday, October 15, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Wednesday, October 9, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Thursday, September 19, 2024

Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia Submitted protocol to FDA for TRANQUILITY In-Care pivotal Phase 3 trial for a

Thursday, September 19, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Thursday, September 19, 2024

Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.